Kailera Therapeutics Inc(KLRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 56.26% | Shs Outstand | 129.6M | Perf Week | 3.87% |
| Market Cap | 1.74B | Forward P/E | - | EPS next Y | -2.1% | Insider Trans | - | Shs Float | 56.7M | Perf Month | 22.11% |
| Enterprise Value | 0.83B | PEG | - | EPS next Q | -1.01 | Inst Own | 44.09% | Short Float | 14.66% | Perf Quarter | -21.29% |
| Income | - | P/S | - | EPS this Y | -202.7% | Inst Trans | 79.24% | Short Ratio | 8.28 | Perf Half Y | -45.8% |
| Sales | - | P/B | 1.56 | EPS next 5Y | - | ROA | - | Short Interest | 8.32M | Perf YTD | -48.38% |
| Book/sh | 8.63 | P/C | 1.9 | EPS past 3/5Y | - | ROE | - | 52W High | -52.46% ($28.23) | Perf Year | - |
| Cash/sh | 7.07 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 37.5% ($9.76) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 5.63% 8.04% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.87 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.11 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 57.64 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.11 | Sales Q/Q | - | SMA20 | 14.84% ($11.69) | Beta | - | Target Price | $42.75 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/12 | SMA50 | -0.47% ($13.48) | Rel Volume | 0.87 | Prev Close | $13.13 |
| Employees | 145 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -21.56% - | SMA200 | -25.64% ($18.05) | Avg Volume(3M) | 1.00M | Price | $13.42 |
| IPO | 2026/4/17 | Option/Short | Yes/Yes | Trades | 6496 | Volume | 877,072 | Change | 2.21% |
💉 This is a US clinical-stage biotech company developing obesity therapeutics. It focuses on next-generation obesity treatments that target appetite and metabolism-regulating hormone pathways, with a pipeline spanning both once-weekly injectables and oral formulations. The company is pursuing entry into the rapidly growing obesity treatment market, centered on a late-stage clinical lead candidate.
Over the past 1 year, on the lower side
52% below its 1-year high.
Traded about as much as usual. That is 87% of its average volume.
Growth has stalled
Earnings are expected to grow by -202.7% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 44.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #115 of 594 in the industry
Based on market cap of $2B.
MAZE#113 Maze Therapeutics Inc $2B PER - 
MESO#114 Mesoblast Ltd ADR $2B PER - KLRA#115 Kailera Therapeutics Inc $2B PER - 
QURE#116 uniQure NV $2B PER - 
NBTX#117 Nanobiotix ADR $2B PER - 
FAQ
What kind of company is KLRA?
KLRA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KLRA?
The market cap of KLRA is approximately $1.7B, ranking 2,176 within its sector.
What is the 52-week high and low for KLRA?
KLRA has recorded a 52-week high of $28.23 and a low of $9.76.
